Compare Microchip Technology Inc. (MCHP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Sanofi SA — how do they compare? Microchip Technology Inc. trades at $75.55 (market cap $41.01B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.3× Microchip Technology Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Sanofi SA for 94 Days on average.
| MCHP | SNY | |
|---|---|---|
Market Cap | $41.01B | $95.18B |
Volume | 9,972,516 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $102.97 | $52.34 |
52-Week Low | $49.02 | $39.51 |
Typical Hold Time | 63 Days | 94 Days |
Enterprise Value | $46.13B | $114.48B |
Dividend Yield | 2.41% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 3.2% over 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025, though it has beaten EPS estimates in recent quarters. Analyst consensus is strongly bullish with a $110.50 price target, supported by positive news on product expansions in Ethernet and 48V power portfolios and the completion of the Hailo acquisition.
The outlook is mixed: strong analyst support and strategic expansions in high-growth areas like AI and automotive present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. Investor sentiment is cautiously optimistic amid sector tailwinds.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
